scispace - formally typeset
Search or ask a question
Author

Gustavs Latkovskis

Bio: Gustavs Latkovskis is an academic researcher from University of Latvia. The author has contributed to research in topics: Population & Myocardial infarction. The author has an hindex of 15, co-authored 55 publications receiving 4443 citations.


Papers
More filters
Journal ArticleDOI
François Mach, Colin Baigent, Alberico L. Catapano, Konstantinos C. Koskinas1, Manuela Casula, Lina Badimon1, M. John Chapman, Guy De Backer, Victoria Delgado, Brian A. Ference, Ian D. Graham, Alison Halliday, Ulf Landmesser, Borislava Mihaylova, Terje R. Pedersen, Gabriele Riccardi, Dimitrios J. Richter, Marc S. Sabatine, Marja-Riitta Taskinen, Lale Tokgozoglu, Olov Wiklund, Christian Mueller, Heinz Drexel, Victor Aboyans, Alberto Corsini, Wolfram Doehner, Michel Farnier, Bruna Gigante, Meral Kayıkçıoğlu, Goran Krstacic, Ekaterini Lambrinou, Basil S. Lewis, Josep Masip, Philippe Moulin, Steffen E. Petersen, Anna Sonia Petronio, Massimo F Piepoli, Xavier Pintó, Lorenz Räber, Kausik K. Ray, Željko Reiner, Walter F Riesen, Marco Roffi, Jean-Paul Schmid, Evgeny Shlyakhto, Iain A. Simpson, Erik S.G. Stroes, Isabella Sudano, Alexandros D Tselepis, Margus Viigimaa, Cecile Vindis, Alexander Vonbank, Michal Vrablik, Mislav Vrsalovic, José Luis Zamorano, Jean-Philippe Collet, Stephan Windecker, Veronica Dean, Donna Fitzsimons, Chris P Gale, Diederick E. Grobbee, Sigrun Halvorsen, Gerhard Hindricks, Bernard Iung, Peter Jüni, Hugo A. Katus, Christophe Leclercq, Maddalena Lettino, Béla Merkely, Miguel Sousa-Uva, Rhian M. Touyz, Djamaleddine Nibouche, Parounak H. Zelveian, Peter Siostrzonek, Ruslan Najafov, Philippe van de Borne, Belma Pojskic, Arman Postadzhiyan, Lambros Kypris, Jindřich Špinar, Mogens Lytken Larsen, Hesham Salah Eldin, Timo E. Strandberg, Jean Ferrières, Rusudan Agladze, Ulrich Laufs, Loukianos S. Rallidis, Laszlo Bajnok, Thorbjorn Gudjonsson, Vincent Maher, Yaakov Henkin, Michele Massimo Gulizia, Aisulu Mussagaliyeva, Gani Bajraktari, Alina Kerimkulova, Gustavs Latkovskis, Omar Hamoui, Rimvydas Šlapikas, Laurent Visser, P. Dingli, Victoria Ivanov, Aneta Boskovic, Mbarek Nazzi, Frank L.J. Visseren, Irena Mitevska, Kjetil Retterstøl, Piotr Jankowski, Ricardo Fontes-Carvalho, Dan Gaita, Marat V. Ezhov, Marina Foscoli, Vojislav Giga, Daniel Pella, Zlatko Fras, Leopoldo Pérez de Isla, Emil Hagström, Roger Lehmann, Leila Abid, Oner Ozdogan, Olena Mitchenko, Riyaz S. Patel 

4,069 citations

Journal ArticleDOI
Marco Valgimigli, Héctor Bueno, Robert A. Byrne, Jean-Philippe Collet, Francesco Costa, Anders Jeppsson, Peter Jüni, Adnan Kastrati, Philippe Kolh1, Laura Mauri, Gilles Montalescot, Franz-Josef Neumann, Mate Petricevic, Marco Roffi, Philippe Gabriel Steg, Stephan Windecker, José Luis Zamorano, Glenn N. Levine, Lina Badimon1, Pascal Vranckx, Stefan Agewall, Felicita Andreotti, Elliott M. Antman, Emanuele Barbato, Jean-Pierre Bassand, Raffaele Bugiardini, Mustafa Cikirikcioglu, Thomas Cuisset, Michele De Bonis, Victora Delgado2, Donna Fitzsimons, Oliver Gaemperli, Nazzareno Galiè, Martine Gilard, Christian W. Hamm, Borja Ibanez, Bernard Iung, Stefan James, Juhani Knuuti, Ulf Landmesser, Christophe Leclercq, Maddalena Lettino, Gregory Y.H. Lip, Massimo F Piepoli, Luc Pierard1, Markus Schwerzmann1, Udo Sechtem, Iain A. Simpson, Miguel Sousa Uva, Eugenio Stabile, Robert F. Storey, Michal Tendera, Frans Van de Werf, Freek W.A. Verheugt, Victor Aboyans, Antonio Coca, I M Coman, Veronica Dean, Victoria Delgado, Gerhard Hindricks, Hugo A. Katus, Patrizio Lancellotti1, Theresa McDonagh, Piotr Ponikowski, Dimitrios J. Richter, Evgeny Shlyakhto, Franz Xaver Roithinger, Farid Aliyev, Valeriy Stelmashok, Walter Desmet, Arman Postadzhiyan, Georgios P Georghiou, Zuzana Motovska, Erik Lerkevang Grove, Toomas Marandi, Tuomas Kiviniemi, Sasko Kedev, Steffen Massberg, Dimitrios Alexopoulos, Róbert Gábor Kiss, Ingibjorg Jona Gudmundsdottir, Eugene P. McFadden, Eli I. Lev, Leonardo De Luca, Akhmetzhan Sugraliyev, Edmond Haliti, Erkin M. Mirrakhimov, Gustavs Latkovskis, Birute Petrauskiene, Steve Huijnen, Caroline Jane Magri, Rhizlan Cherradi, Jurriën M. ten Berg, Jan Eritsland, Andrzej Budaj, Carlos Aguiar, Dmitry Duplyakov, Marco Zavatta, Nebojsa M Antonijevic, Zlatko Fras, Antonio Tello Montoliu, Christoph Varenhorst, Dimitri Tsakiris, Faouzi Addad, Sinan Aydogdu, Alexander Parkhomenko, Tim Kinnaird 
TL;DR: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed in collaboration with EACTS is described in this paper.
Abstract: 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS : The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

1,954 citations

Journal ArticleDOI
TL;DR: The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who have not achieved lipid goals, and patients with statin intolerance.
Abstract: In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting.

274 citations

Journal ArticleDOI
TL;DR: The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction.

202 citations

Journal ArticleDOI
TL;DR: This research presents a novel and scalable approach called “SmartCardiology,” which aims to provide real-time information about the activity of the autonomic nervous system and its role in cardiac arrest.
Abstract: 1.1. Cardiovascular disease and dyslipidemia: prevalence and global economic impact Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, reaching 31% of deaths in 2012 [1]. In particular, atherosclerosis and ischemic heart disease (IHD) are the main causes of premature death in Europe and are responsible for 42% of deaths in women and 38% in men under 75 years old [2]. The global economic impact of CVD is estimated to have been US $906 billion in 2015 and is expected to rise by 22% by 2030 [3]. Cardiovascular diseases also represent the major cause of disability in developed countries. It has been estimated that their growing burden could lead to a global increase in loss of disability-adjusted life years (DALYs), from a loss of 85 million DALYs in 1990 to a loss of ~150 million DALYs in 2020, becoming a major non-psychological cause of lost productivity [4]. Several risk factors contribute to the etiology and development of CVD; they are divided into those modifiable through lifestyle changes or by taking a pharmacologic treatment (e.g. for hypertension, smoking, diabetes mellitus, hypercholesterolemia) and those that are not modifiable (age, male gender, and family history) [5]. Elevated total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) blood concentrations are the major modifiable risk factors for coronary heart disease (CHD), whereas high concentrations of plasma high-density lipoprotein cholesterol (HDL-C) in certain conditions are considered protective [6]. Moreover, LDL-C remains a fundamental CV risk factor (and a main target of therapy) even when statins are largely used in the general population [7]. An examination of the data of 18 053 participants aged ≥ 20 years who participated in the National Health and Nutrition Examination Surveys (NHANES) from 1999 to 2006 showed that the unadjusted prevalence of hypercholesterolemia ranged from 53.2% to 56.1% in United States adults [8]. Differences related to gender and race or ethnicity were observed; in particular, a lower rate of control was found among women than men and lower rates of having a cholesterol check and being told about hypercholesterolemia were reported by African Americans and Mexican Americans than whites [8]. A recent report from the American Heart Association confirmed that in the US only 75.7% of children and 46.6% of adults present targeted TC levels (TC < 170 mg/dl for children and < 200 mg/dl for adults, in untreated individuals) [9]. The pattern is similar in other Western countries [10, 11].

191 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: In this article, the authors present guidelines for the management of patients with coronary artery disease (CAD), which is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries.
Abstract: Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1.

3,448 citations

Journal ArticleDOI
TL;DR: A correction has been published: European Heart Journal, ehaa895, https://doi.org/10.1093/eurheartj/ehaa-895.
Abstract: A correction has been published: European Heart Journal, ehaa895, https://doi.org/10.1093/eurheartj/ehaa895

2,361 citations

Journal ArticleDOI
TL;DR: Document reviewers: Hind Beheiry (Sudan), Irina Chazova (Russia), Albertino Damasceno (Mozambique), Anna Dominiczak (UK), Stephen Harrap (Australia), Hiroshi Itoh (Japan), Tazeen Jafar (Singapore), Marc Jaffe (USA), Patricio Jaramillo-Lopez (Colombia), Kazuomi Kario (Japan).
Abstract: Document reviewers: Hind Beheiry (Sudan), Irina Chazova (Russia), Albertino Damasceno (Mozambique), Anna Dominiczak (UK), Anastase Dzudie (Cameroon), Stephen Harrap (Australia), Hiroshi Itoh (Japan), Tazeen Jafar (Singapore), Marc Jaffe (USA), Patricio Jaramillo-Lopez (Colombia), Kazuomi Kario (Japan), Giuseppe Mancia (Italy), Ana Mocumbi (Mozambique), Sanjeevi N.Narasingan (India), Elijah Ogola (Kenya), Srinath Reddy (India), Ernesto Schiffrin (Canada), Ann Soenarta (Indonesia), Rhian Touyz (UK), Yudah Turana (Indonesia), Michael Weber (USA), Paul Whelton (USA), Xin Hua Zhang, (Australia), Yuqing Zhang (China).

1,657 citations

Journal ArticleDOI
Frank L.J. Visseren, François Mach, Yvo M. Smulders, David Carballo, Konstantinos C. Koskinas, Maria Bäck, Athanase Benetos, Alessandro Biffi, José-Manuel Boavida1, Davide Capodanno, Bernard Cosyns, Carolyn Crawford, Constantinos H. Davos, Ileana Desormais, Emanuele Di Angelantonio, Oscar H. Franco, Sigrun Halvorsen, FD Richard Hobbs, Monika Hollander, Ewa A. Jankowska, Matthias Michal, Simona Sacco, Naveed Sattar, Lale Tokgozoglu, Serena Tonstad, Konstantinos P Tsioufis2, Ineke van Dis, Isabelle C. Van Gelder, Christoph Wanner3, Bryan Williams, Guy De Backer, Vera Regitz-Zagrosek, Anne Hege Aamodt, Magdy Abdelhamid, Victor Aboyans, Christian Albus, Riccardo Asteggiano, Magnus Bäck, Michael A. Borger, Carlos Brotons, Jelena Čelutkienė, Renata Cifkova, Maja Čikeš, Francesco Cosentino, Nikolaos Dagres, Tine De Backer, Dirk De Bacquer, Victoria Delgado, Hester Den Ruijter, Paul Dendale, Heinz Drexel, Volkmar Falk, Laurent Fauchier, Brian A. Ference, Jean Ferrières, Marc Ferrini4, Miles Fisher4, Danilo Fliser3, Zlatko Fras, Dan Gaita, Simona Giampaoli, Stephan Gielen, Ian D. Graham, Catriona Jennings, Torben Jørgensen, Alexandra Kautzky-Willer, Maryam Kavousi, Wolfgang Koenig, Aleksandra Konradi, Dipak Kotecha, Ulf Landmesser, Madalena Lettino, Basil S. Lewis, Aleš Linhart, Maja-Lisa Løchen1, Konstantinos Makrilakis1, Giuseppe Mancia2, Pedro Marques-Vidal, John W. McEvoy, Paul McGreavy, Béla Merkely, Lis Neubeck, Jens Cosedis Nielsen, Joep Perk, Steffen E. Petersen, Anna Sonia Petronio, Massimo F Piepoli, Nana Pogosova, Eva Prescott, Kausik K. Ray, Zeljko Reiner, Dimitrios J. Richter, Lars Rydén, Evgeny Shlyakhto, Marta Sitges, Miguel Sousa-Uva, Isabella Sudano, Monica Tiberi, Rhian M. Touyz, Andrea Ungar, W. M. Monique Verschuren, Olov Wiklund, David A. Wood, José Luis Zamorano, Carolyn A Crawford, Oscar H Franco Duran 

1,650 citations

Journal ArticleDOI
TL;DR: Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on antICOagulation.
Abstract: The current manuscript is the second update of the original Practical Guide, published in 2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-651; Heidbuchel et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-1507]. Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on anticoagulation. Both physicians and patients are becoming more accustomed to the use of these drugs in clinical practice. However, many unresolved questions on how to optimally use these agents in specific clinical situations remain. The European Heart Rhythm Association (EHRA) set out to coordinate a unified way of informing physicians on the use of the different NOACs. A writing group identified 20 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence. The 20 topics are as follows i.e., (1) Eligibility for NOACs; (2) Practical start-up and follow-up scheme for patients on NOACs; (3) Ensuring adherence to prescribed oral anticoagulant intake; (4) Switching between anticoagulant regimens; (5) Pharmacokinetics and drug-drug interactions of NOACs; (6) NOACs in patients with chronic kidney or advanced liver disease; (7) How to measure the anticoagulant effect of NOACs; (8) NOAC plasma level measurement: rare indications, precautions, and potential pitfalls; (9) How to deal with dosing errors; (10) What to do if there is a (suspected) overdose without bleeding, or a clotting test is indicating a potential risk of bleeding; (11) Management of bleeding under NOAC therapy; (12) Patients undergoing a planned invasive procedure, surgery or ablation; (13) Patients requiring an urgent surgical intervention; (14) Patients with AF and coronary artery disease; (15) Avoiding confusion with NOAC dosing across indications; (16) Cardioversion in a NOAC-treated patient; (17) AF patients presenting with acute stroke while on NOACs; (18) NOACs in special situations; (19) Anticoagulation in AF patients with a malignancy; and (20) Optimizing dose adjustments of VKA. Additional information and downloads of the text and anticoagulation cards in different languages can be found on an EHRA website (www.NOACforAF.eu).

1,499 citations